Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Acq. announced
Inv. presentation
Mirum Pharmaceuticals, Inc. (MIRM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - $37.5 million total revenue, including net product sales for LIVMARLI ® oral solution of $32.5 million, for second quarter 2023 - Acquiring CHENODAL ® and CHOLBAM ® , advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise - Four late-stage clinical trial data readouts expected later this year - Conference call to provide business updates today, August 3 at 1:30 p.m. PT/4:30 p.m. ET"
05/04/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI ® oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET"
03/08/2023 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI ® oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million - Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET"
11/09/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update - Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI ® oral solution of $10.9 million. - Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET"
03/09/2022 8-K Quarterly results
11/15/2021 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - U.S. commercial launch underway following U.S. FDA approval of LIVMARLITM oral solution - Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort (p - The Lancet published data from the pivotal LIVMARLI ICONIC study demonstrating significant and durable responses in pruritus and other clinically meaningful improvements in patients with ALGS - Conference call to provide business updates and discuss data presented at AASLD today, November 15 at 1:30 p.m. PT/4:30 p.m. ET"
08/05/2021 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update - NDA for maralixibat for cholestatic pruritus in Alagille syndrome under priority review; PDUFA date is September 29, 2021 - Commercial preparations complete in anticipation of U.S. launch of maralixibat in ALGS - Conference call to provide business update today, August 5 at 1:30 p.m. PT/4:30 p.m. ET"
05/06/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates - On track to begin rolling submission of NDA for maralixibat in Alagille Syndrome in third quarter 2020 -"
11/06/2019 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome Granted"
08/28/2019 8-K Quarterly results
Docs: "Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy